Evidence map›Paper›PMID 38123556›Full record

ArticleNature communications2023

Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19.

Rae Maeda, Natsumi Seki, Yoshifumi Uwamino, Masatoshi Wakui, Yu Nakagama, Yasutoshi Kido, Miwa Sasai, Shu Taira, Naoya Toriu, Masahiro Yamamoto and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts.Metabolomics : Official journal of the Metabolomic Society · 2026
    Review
  4. Purine salvage pathway protects CD8Nature immunology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Rae Maeda *Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Natsumi Seki *Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshifumi UwaminoDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Yu NakagamaDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yasutoshi KidoDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Miwa SasaiResearch Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0001-6440-3958
Shu TairaFaculty of Food and Agricultural Sciences, Fukushima University, Fukushima, Japan.
Naoya ToriuDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masahiro YamamotoResearch Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0002-6821-2785
Yoshiharu MatsuuraResearch Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0001-9091-8285
Jun UchiyamaResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
Genki YamaguchiResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
Makoto HirakawaResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
Yun-Gi KimResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
Masayo MishimaDepartment of Biochemistry, Keio University School of Medicine, Tokyo, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-0339-9008
Makoto SuematsuDepartment of Biochemistry, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-7165-6336
Yuki SugiuraCenter for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan. yuki.sgi@gmail.com.ORCID 0000-0002-6983-8958
Keio University · JPKyoto University · JPOsaka International Cancer Institute · JPOsaka Metropolitan University · JPFukushima University · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP20zf0127003 and JP20gm1210009MEXT | Japan Society for the Promotion of Science (JSPS) 22H02833
6 · The paper itself

Abstract

Effective early-stage markers for predicting which patients are at risk of developing SARS-CoV-2 infection have not been fully investigated. Here, we performed comprehensive serum metabolome analysis of a total of 83 patients from two cohorts to determine that the acceleration of amino acid catabolism within 5 days from disease onset correlated with future disease severity. Increased levels of de-aminated amino acid catabolites involved in the de novo nucleotide synthesis pathway were identified as early prognostic markers that correlated with the initial viral load. We further employed mice models of SARS-CoV2-MA10 and influenza infection to demonstrate that such de-amination of amino acids and de novo synthesis of nucleotides were associated with the abnormal proliferation of airway and vascular tissue cells in the lungs during the early stages of infection. Consequently, it can be concluded that lung parenchymal tissue remodeling in the early stages of respiratory viral infections induces systemic metabolic remodeling and that the associated key amino acid catabolites are valid predictors for excessive inflammatory response in later disease stages.

Indexed as

COVID-19PneumoniaAmino AcidsAnimalsHumansMiceRNA, ViralSARS-CoV-2Amino AcidsRNA, Viral

Identifiers

PMID38123556
PMCPMC10733290
OpenAlexW4390002487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.